The abstract is read at the publisher; the summary is JClub's.
NP137 Fab and NET1 peptide competitors disrupt the netrin-1–UNC5B complex by blocking key interface contacts and heparin-stabilized binding sites.
- Why it matters: The netrin-1–UNC5B interaction supports cancer progression, but the precise molecular interface and how NP137 blocks it were unclear.
- What they did: Using integrative structural and quantitative biophysical analyses, the study mapped the netrin-1–UNC5B binding interface, then tested how NP137 sterically inhibits contact points and guided peptide design to target shared heparin-binding sites.
- The result: The mechanistic model shows how therapeutic antibodies and engineered peptides can interfere with netrin-1 signaling, supporting targeted intervention strategies in netrin-1–driven malignancies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.